Recommendation for Novartis’ chronic myeloid leukaemia STAMP inhibitor - Drug Informics

Post Top Ad

Friday, 1 July 2022

Recommendation for Novartis’ chronic myeloid leukaemia STAMP inhibitor

Chronic myeloid leukaemia therapy Scemblix receives NICE final draft recommendation in Britain

from PharmaTimes: News RSS https://ift.tt/GhyY0n2

No comments:

Post a Comment

Post Top Ad